Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesOrthopedics/MusculoskeletalBCBS Massachusetts Knee Shock Absorber Policy | Op…
    Ask Trek AI about this page
    ModifiedBlue Cross Blue Shield - MassachusettsPolicy 253

    Implantable Shock Absorber for Treatment of Knee Osteoarthritis

    Customize your policy alerts

    Sign up for Blue Cross Blue Shield - Massachusetts Policy 253 alerts

    Get alerted when Policy 253 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs coverage of implantable shock absorbers used to treat knee osteoarthritis for Blue Cross Blue Shield of Massachusetts commercial and Medicare Advantage members. The technology is classified as investigational and is not a covered service for the listed products.

    Policy Summary
    PayerBlue Cross Blue Shield - Massachusetts
    PolicyImplantable Shock Absorber for Treatment of Knee Osteoarthritis
    Policy CodePolicy 253
    Change TypeNew policy
    Effective DateOctober 1, 2026
    Last ReviewOct 1, 2026
    Next Review DateN/A
    Key ActionObtain precertification or preauthorization for all inpatient services described in this policy.
    SourceLink
    POLICY UPDATE CHANGES

    A new medical policy was created classifying implantable shock absorbers for treatment of knee osteoarthritis as investigational.

    InvestigationalCoverage status
    All listed products

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Product lines affected
    April 2023FDA authorization
    24 monthsPivotal study duration
    5 yearsPost-market follow-up
    13Supporting references

    Coverage Determination

    Investigational use

    Not covered because the service is considered investigational.

    Investigational implantable shock absorber: The use of implantable shock absorbers as a treatment for knee osteoarthritis is considered investigational.

    Applies to Commercial Managed Care (HMO and POS), Commercial PPO and Indemnity, Medicare HMO Blue, and Medicare PPO Blue members.

    For outpatient services described in this policy, implantable shock absorbers for treatment of knee osteoarthritis are not a covered service for Commercial Managed Care (HMO and POS), Commercial PPO and Indemnity, Medicare HMO Blue, and Medicare PPO Blue products.

    Investigational Coding

    Investigational HCPCS CodeHCPCSExperimental
    No codes listed

    Authorization and Coverage Actions

    Prior Authorization

    Obtain inpatient precertification or preauthorization

    Precertification or preauthorization is required for all products when a service described in this policy is performed inpatient.

    Prior Authorization

    Review outpatient product requirements

    For outpatient procedures described in this policy, review the applicable product requirements before proceeding. The listed products identify the procedure as not a covered service.

    Denial Risk

    Investigational service is not covered

    Implantable shock absorbers used as a treatment for knee osteoarthritis are considered investigational and are not covered for the listed commercial and Medicare Advantage products.

    Denial Risk

    Confirm product-specific noncoverage

    For outpatient services described in this policy, the procedure is identified as not a covered service for the following products: Commercial Managed Care, Commercial PPO and Indemnity, Medicare HMO Blue, and Medicare PPO Blue.

    Denial Risk

    Recognize insufficient clinical evidence

    The evidence is insufficient to determine that implantable shock absorbers improve net health outcomes. Available evidence is primarily a single nonrandomized cohort with a historical control, and long-term device safety and durability data beyond 24 months are unavailable from peer-reviewed publications.

    Clinical Background

    Knee osteoarthritis is a degenerative joint disease associated with loss of articular cartilage, changes in the subchondral bone, inflammation, and formation of osteophytes. These changes can contribute to pain, stiffness, and functional limitation.

    Technology and Evidence Definitions

    Implantable Shock Absorber
    DeviceAn implantable shock absorber for the knee intended to relieve pain and improve function in individuals with knee osteoarthritis.
    Intended useDesigned for individuals who have failed nonsurgical treatment and are not candidates for, or are unwilling to undergo, joint replacement surgery.
    U.S. authorized deviceThe MISHA Knee System is the first and currently only U.S. FDA-authorized implantable shock absorber for this indication.
    MISHA Knee System Indication
    FDA authorizationThe MISHA Knee System received FDA De Novo authorization in April 2023.
    Indicated populationPeople with medial knee osteoarthritis who have failed to find relief from nonsurgical or surgical treatment and continue to experience pain that interferes with daily activities.
    Policy Summary
    PayerBlue Cross Blue Shield - Massachusetts
    PolicyImplantable Shock Absorber for Treatment of Knee Osteoarthritis
    Policy CodePolicy 253
    Change TypeNew policy
    Effective DateOctober 1, 2026
    Last ReviewOct 1, 2026
    Next Review DateN/A
    Key ActionObtain precertification or preauthorization for all inpatient services described in this policy.
    SourceLink
    On This Page
    Coverage DeterminationInvestigational CodingAuthorization and Coverage ActionsClinical BackgroundTechnology and Evidence Definitions
    Joint replacement statusThe indicated population is ineligible for or unwilling to undergo joint replacement because of age or absence of advanced osteoarthritis.
    Calypso Study
    Study designThe Calypso Study was a prospective, multicenter, open-label cohort study conducted at 10 centers across the United States and Europe.
    ComparisonThe study compared the MISHA Knee System with high tibial osteotomy (HTO).
    Study durationThe study reported outcomes over 24 months.